Page last updated: 2024-12-05

mephobarbital

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Mephobarbital: A barbiturate that is metabolized to PHENOBARBITAL. It has been used for similar purposes, especially in EPILEPSY, but there is no evidence mephobarbital offers any advantage over PHENOBARBITAL. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

mephobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at N-1 by a methyl group and at C-5 by ethyl and phenyl groups. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID8271
CHEMBL ID45029
CHEBI ID6758
SCHEMBL ID35624
MeSH IDM0013433

Synonyms (105)

Synonym
isonal
5-ethyl-1-methyl-5-phenyl-pyrimidine-2,4,6-trione
barbituric acid, 5-ethyl-1-methyl-5-phenyl-
methylphenobarbital
n-methylphenobarbital
CHEBI:6758 ,
5-ethyl-1-methyl-5-phenylpyrimidine-2,4,6(1h,3h,5h)-trione
mephobarbitone
methylphenobarbitalum
2,4,6(1h,3h,5h)-pyrimidinetrione, 5-ethyl-1-methyl-5-phenyl-
5-ethyl-1-methyl-5-phenylbarbituric acid
5-ethyl-1-methyl-5-phenyl-2,4,6(1h,3h,5h)-pyrimidinetrione
1-methylphenobarbital
metilfenobarbital
mebaral
OPREA1_133475
n-methylphenolbarbitol
methyl-calminal
einecs 204-085-7
prominaletten
methylphenobarbitalum [inn-latin]
enfenemal
n-methylethylphenylbarbituric acid
5-ethyl-n-methyl-5-phenylbarbituric acid
prominalum
mephytal
metilfenobarbital [inn-spanish]
prominal
methylphenolbarbital
brn 0256144
enphenemalum
methylphenylbarbituric acid
n-methyl-5-phenyl-5-ethylbarbital
dea no. 2250
menta-bal
phemitone
metyna
methylphenobarbitonum
1-methyl-5-ethyl-5-phenylbarbituric acid
5-ethyl-5-phenyl-n-methyl-bartituric acid
phemiton
mephobarbital [jan]
morbusan
metylfenemal
hsdb 3579
5-phenyl-5-ethyl-3-methylbarbituric acid
n-ethylmethylphenylbarbituric acid
1-methyl-5-phenyl-5-ethylbarbituric acid
metilfenobarbitale [dcit]
isonal (roussel)
C07829
mephobarbital
115-38-8
methylphenobarbitone
NCGC00159357-02
enphenemal
DB00849
NCGC00159357-03
D00700
mephobarbital (jan/usp)
methylphenobarbital (inn)
mebaral (tn)
5-ethyl-1-methyl-5-phenyl-1,3-diazinane-2,4,6-trione
alarqzqtbtvljv-uhfffaoysa-
inchi=1/c13h14n2o3/c1-3-13(9-7-5-4-6-8-9)10(16)14-12(18)15(2)11(13)17/h4-8h,3h2,1-2h3,(h,14,16,18)
CHEMBL45029
mephobarbital civ
phemetone
AKOS002254670
A803425
STK732046
cas-115-38-8
dtxsid4023258 ,
tox21_111600
dtxcid403258
meberal
methyl phenobarbitone
5-24-09-00294 (beilstein handbook reference)
methylphenobarbital [inn]
unii-5nc67nu76b
5nc67nu76b ,
metilfenobarbitale
mephobarbital [usp:jan]
mephobarbital civ [usp-rs]
mephobarbital [hsdb]
mephobarbital [mi]
mephobarbital [vandf]
methylphenobarbital [who-dd]
methylphenobarbital [mart.]
mephobarbital [usp monograph]
methylphenobarbital [ep monograph]
SCHEMBL35624
cambridge id 5240602
(.+/-.)-mephobarbital
ALARQZQTBTVLJV-UHFFFAOYSA-N
hexahydropyrimidine-2,4,6-trione,1-methyl-5-ethyl-5-phenyl-
1-methyl-5-ethyl-5-phenyl-pyrimidine-2,4,6-trione
phenobarbital, mono-methyl
n-methyl-5-phenyl-5-ethylbarbituric acid
mephobarbital, united states pharmacopeia (usp) reference standard
methylphenobarbital, 1.0 mg/ml in methanol, certified reference material
methylphenobarbital, european pharmacopoeia (ep) reference standard
methylphenobarbital 0.1 mg/ml in methanol
methylphenobarbital 1.0 mg/ml in methanol
Q411697

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36

Pharmacokinetics

ExcerptReferenceRelevance
" The apparent total body clearance of R-mephobarbital was much greater and the elimination half-life was much shorter in the young men compared with the other three groups."( The influence of age and gender on the stereoselective metabolism and pharmacokinetics of mephobarbital in humans.
Hooper, WD; Qing, MS, 1990
)
0.77

Bioavailability

ExcerptReferenceRelevance
"The pharmacokinetics and bioavailability of mephobarbital have been studied in 2 volunteers."( Pharmacokinetics and bioavailability of methylphenobarbital in man.
Eadie, MJ; Hooper, WD; Kunze, HE, 1981
)
0.52
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" The one statistically significant interaction found was that in which phenytoin dosage decreased plasma carbamazepine concentrations."( Interactions between anticonvulsants.
Eadie, MJ; Lander, CM; Tyrer, JH, 1975
)
0.25
" The majority of the patients receiving Comital-L tablets showed low serum levels of phenytoin and high serum levels of phenobarbital, while patients treated with the usual daily dosage of Hydantol-F tablets showed adequate therapeutic serum levels of both phenytoin and phenobarbital."( Serum levels of phenytoin and phenobarbital in epileptic patients treated with mixture antiepileptic tablets, Comital-L or Hydantol-F.
Hattori, M; Kazamatsuri, H, 1979
)
0.26
" 4 In individual patients, within the limits of dosage studied, the relation between plasma phenobarbitone level and drug dose was not rectilinear if phenobarbitone itself was taken, but was rectilinear if methylphenobarbitone was taken."( Factors influencing plasma phenobarbitone levels in epileptic patients.
Eadie, MJ; Hooper, WD; Lander, CM; Tyrer, JH, 1977
)
0.26
" Phenytoin (PHT) dosage had to be increased in 85% of pregnancies in which the drug was received, carbamazepine (CBZ) dosage in 70%, and phenobarbital (PB) or methylphenobarbital (MPB) dosage in 85%, in an attempt to prevent or correct a fall in plasma concentrations of the respective drugs as pregnancy progressed."( Plasma antiepileptic drug concentrations during pregnancy.
Eadie, MJ; Lander, CM,
)
0.13
"The simultaneous dosing of two drugs with co-regulated genetic polymorphisms determined by a single cytochrome P-450 isozyme could result in competitive inhibition of metabolism."( Polymorphic metabolism of mephenytoin in man: pharmacokinetic interaction with a co-regulated substrate, mephobarbital.
Branch, RA; Hall, SD; Jacqz, E; Wilkinson, GR, 1986
)
0.49
" The major conclusions of the study were that mephobarbital is reasonably well absorbed following oral dosing and that some 35% or so of the dose (by either route) is converted to the recently identified metabolite, p-hydroxymephobarbital."( Pharmacokinetics and bioavailability of methylphenobarbital in man.
Eadie, MJ; Hooper, WD; Kunze, HE, 1981
)
0.52
" When one compound ofa pharmacologically active substance is replaced by a different compound, the dosage should be corrected for both the chemical structure, such as the molecular weight, and the pharmacokinetic properties such as absorption, metabolism and biological availability."( [Intoxication due to replacement of the precursor methylphenobarbital by phenobarbital].
Heeringa-Karreman, M; van Munster, ET, 2006
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
anticonvulsantA drug used to prevent seizures or reduce their severity.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
barbituratesMembers of the class of pyrimidones consisting of pyrimidine-2,4,6(1H,3H,5H)-trione (barbituric acid) and its derivatives. Largest group of the synthetic sedative/hypnotics, sharing a characteristic six-membered ring structure.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AR proteinHomo sapiens (human)Potency26.60320.000221.22318,912.5098AID743040
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency6.30960.01237.983543.2770AID1346984
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency10.68220.000214.376460.0339AID720691
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency28.18380.035520.977089.1251AID504332
nuclear receptor subfamily 1, group I, member 2Rattus norvegicus (Norway rat)Potency14.12540.10009.191631.6228AID1346983
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency25.09990.005612.367736.1254AID624044
lamin isoform A-delta10Homo sapiens (human)Potency0.44670.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (37)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID227718Binding energy by using the equation deltaG obsd = -RT ln KD1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Functional group contributions to drug-receptor interactions.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID625295Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in Pfizer data2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID698864Aqueous solubility in 0.01 M Tris/HCl buffer at pH 7.4 by HPLC2012Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14
Allyl m-trifluoromethyldiazirine mephobarbital: an unusually potent enantioselective and photoreactive barbiturate general anesthetic.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID346025Binding affinity to beta cyclodextrin2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Convenient QSAR model for predicting the complexation of structurally diverse compounds with beta-cyclodextrins.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID227699Virtual screen for compounds with anticonvulsant activity2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Topological virtual screening: a way to find new anticonvulsant drugs from chemical diversity.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID698863Partition coefficient, log P of the compound in octanol/buffer at pH 7.4 by UV spectroscopy2012Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14
Allyl m-trifluoromethyldiazirine mephobarbital: an unusually potent enantioselective and photoreactive barbiturate general anesthetic.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159537qHTS screening for TAG (triacylglycerol) accumulators in algae2017Plant physiology, Aug, Volume: 174, Issue:4
Identification and Metabolite Profiling of Chemical Activators of Lipid Accumulation in Green Algae.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (167)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990121 (72.46)18.7374
1990's16 (9.58)18.2507
2000's14 (8.38)29.6817
2010's13 (7.78)24.3611
2020's3 (1.80)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 38.81

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index38.81 (24.57)
Research Supply Index5.23 (2.92)
Research Growth Index4.27 (4.65)
Search Engine Demand Index59.54 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (38.81)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (2.20%)5.53%
Reviews10 (5.49%)6.00%
Case Studies11 (6.04%)4.05%
Observational0 (0.00%)0.25%
Other157 (86.26%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]